130 related articles for article (PubMed ID: 18566232)
21. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
22. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.
Pulaski BA; Smyth MJ; Ostrand-Rosenberg S
Cancer Res; 2002 Aug; 62(15):4406-12. PubMed ID: 12154047
[TBL] [Abstract][Full Text] [Related]
23. A CD44v
Hu J; Li G; Zhang P; Zhuang X; Hu G
Cell Death Dis; 2017 Mar; 8(3):e2679. PubMed ID: 28300837
[TBL] [Abstract][Full Text] [Related]
24. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.
Yae T; Tsuchihashi K; Ishimoto T; Motohara T; Yoshikawa M; Yoshida GJ; Wada T; Masuko T; Mogushi K; Tanaka H; Osawa T; Kanki Y; Minami T; Aburatani H; Ohmura M; Kubo A; Suematsu M; Takahashi K; Saya H; Nagano O
Nat Commun; 2012 Jun; 3():883. PubMed ID: 22673910
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival.
Chen Z; Varney ML; Backora MW; Cowan K; Solheim JC; Talmadge JE; Singh RK
Cancer Res; 2005 Oct; 65(19):9004-11. PubMed ID: 16204074
[TBL] [Abstract][Full Text] [Related]
26. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
27. Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein.
Budagian V; Nanni P; Lollini PL; Musiani P; Di Carlo E; Bulanova E; Paus R; Bulfone-Paus S
Scand J Immunol; 2002 May; 55(5):484-92. PubMed ID: 11975760
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronan-independent lodgment of CD44+ lymphoma cells in lymphoid organs.
Vogt Sionov R; Naor D
Int J Cancer; 1997 May; 71(3):462-9. PubMed ID: 9139885
[TBL] [Abstract][Full Text] [Related]
29. Expression of CD44 splice variants in metastatic and non-metastatic mouse tumour cell lines.
Tkach T; Li E; Bestagno M; Burrone OR
Immunol Lett; 1996 Sep; 52(2-3):81-7. PubMed ID: 8905400
[TBL] [Abstract][Full Text] [Related]
30. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
31. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
[TBL] [Abstract][Full Text] [Related]
32. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.
Wei WZ; Shi WP; Galy A; Lichlyter D; Hernandez S; Groner B; Heilbrun L; Jones RF
Int J Cancer; 1999 May; 81(5):748-54. PubMed ID: 10328228
[TBL] [Abstract][Full Text] [Related]
33. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
[TBL] [Abstract][Full Text] [Related]
34. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
35. Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line.
Cavanaugh PG; Jia L; Zou Y; Nicolson GL
Breast Cancer Res Treat; 1999 Aug; 56(3):203-17. PubMed ID: 10573112
[TBL] [Abstract][Full Text] [Related]
36. The CD44 receptor of the mouse LB T-cell lymphoma: analysis of the isoform repertoire and ligand binding properties by reverse-transcriptase polymerase chain reaction and antisense oligonucleotides.
Wallach SB; Friedmann A; Naor D
Cancer Detect Prev; 2000; 24(1):33-45. PubMed ID: 10757121
[TBL] [Abstract][Full Text] [Related]
37. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.
Walser TC; Rifat S; Ma X; Kundu N; Ward C; Goloubeva O; Johnson MG; Medina JC; Collins TL; Fulton AM
Cancer Res; 2006 Aug; 66(15):7701-7. PubMed ID: 16885372
[TBL] [Abstract][Full Text] [Related]
38. CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions.
Shirure VS; Liu T; Delgadillo LF; Cuckler CM; Tees DF; Benencia F; Goetz DJ; Burdick MM
Am J Physiol Cell Physiol; 2015 Jan; 308(1):C68-78. PubMed ID: 25339657
[TBL] [Abstract][Full Text] [Related]
39. CD44 expression in metastatic and non-metastatic non-small cell lung cancers.
Kargi HA; Kuyucuoğlu MF; Alakavuklar M; Akpinar O; Erk S
Cancer Lett; 1997 Oct; 119(1):27-30. PubMed ID: 18372518
[TBL] [Abstract][Full Text] [Related]
40. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
Yu P; Lee Y; Wang Y; Liu X; Auh S; Gajewski TF; Schreiber H; You Z; Kaynor C; Wang X; Fu YX
J Immunol; 2007 Aug; 179(3):1960-8. PubMed ID: 17641063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
